MENU
+Compare
HELX
ETF ticker: BATS
AS OF
Jun 27 closing price
Price
$27.62
Change
-$0.12 (-0.43%)
Net Assets
11.05M

HELX stock forecast, quote, news & analysis

The investment seeks capital appreciation... Show more

Category: #Health
HELX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for HELX with price predictions
Jun 27, 2025

HELX in upward trend: price rose above 50-day moving average on June 03, 2025

HELX moved above its 50-day moving average on June 03, 2025 date and that indicates a change from a downward trend to an upward trend. In of 39 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on May 29, 2025. You may want to consider a long position or call options on HELX as a result. In of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for HELX just turned positive on May 27, 2025. Looking at past instances where HELX's MACD turned positive, the stock continued to rise in of 43 cases over the following month. The odds of a continued upward trend are .

The 10-day moving average for HELX crossed bullishly above the 50-day moving average on June 09, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where HELX advanced for three days, in of 336 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 249 cases where HELX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for HELX moved out of overbought territory on June 27, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 similar instances where the indicator moved out of overbought territory. In of the 24 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

HELX broke above its upper Bollinger Band on June 10, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), AstraZeneca PLC (NASDAQ:AZN), Bristol-Myers Squibb Co (NYSE:BMY), Regeneron Pharmaceuticals (NASDAQ:REGN), IQVIA Holdings (NYSE:IQV), Exact Sciences Corp (NASDAQ:EXAS), Moderna (NASDAQ:MRNA), Guardant Health (NASDAQ:GH), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Sarepta Therapeutics (NASDAQ:SRPT).

Industry description

The investment seeks capital appreciation. Under normal market conditions, the fund invests at least 80% of its net assets in equity securities of companies that are relevant to its investment theme of genomic advancements. The fund invests predominantly in common stock. Although it may invest across economic sectors, the fund concentrates its investments in health care related industries. It is non-diversified.

Market Cap

The average market capitalization across the Franklin Genomic Advancements ETF ETF is 34.42B. The market cap for tickers in the group ranges from 163.8M to 739.66B. LLY holds the highest valuation in this group at 739.66B. The lowest valued company is VYGR at 163.8M.

High and low price notable news

The average weekly price growth across all stocks in the Franklin Genomic Advancements ETF ETF was 1%. For the same ETF, the average monthly price growth was 7%, and the average quarterly price growth was -6%. WGS experienced the highest price growth at 36%, while SRPT experienced the biggest fall at -15%.

Volume

The average weekly volume growth across all stocks in the Franklin Genomic Advancements ETF ETF was 17%. For the same stocks of the ETF, the average monthly volume growth was 49% and the average quarterly volume growth was 299%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 61
P/E Growth Rating: 74
Price Growth Rating: 55
SMR Rating: 79
Profit Risk Rating: 80
Seasonality Score: 37 (-100 ... +100)
View a ticker or compare two or three
HELX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
Franklin Templeton ETF TrustONE FRANKLIN PARKWAYSAN MATEO
Phone
N/A
Web
etf.franklintempleton.com